How Do Visual Patient Profiles Help Medical Reviews in Complex Oncology Trials?

Dr. Ashok Srivastava, CEO & Chief Medical Officer, ClinFomatrix, and CEO, Cure Pharmaceuticals, Inc.

Dr. Ashok Srivastava has more than 17 years of experience in drug development, medical affairs and commercialization of cancer drugs, including radiopharmaceutical and supportive care, Phase I – IV trials and marketing commercialization of immuno-oncology, hematology, oncology and radio pharmaceutical drugs in the US, EU and Japan. He is a leader in cancer drug development worldwide for Phase II and III clinical trials in many countries. He contributed to 21 Investigational New Drug applications (INDs) and seven New Drug Applications (NDAs) of cancer drugs and supportive care — acquisition/merger of pharma and drugs worth more than $300 million.

Dr. Srivastava played a key role in the dramatic expansion of oncology drugs and developed numerous cancer drugs: Sutent (Sunitinib), Evoxac (Cevimeline HCl), and liposomal doxorubicin (Myocet) in combination with Herceptin and Paclitaxel for HER2 positive metastatic breast cancer patients. He also developed Latuda (Lurasidone) for schizophrenia. He is one of the inventors of the Japanese encephalitis vaccine (IXIARO).

Dr. Srivastava is a leader in innovative, generic and biosimilar drug development, drug safety, pharmacovigilance of hematology, oncology drugs and he has built global drug safety and pharmacovigilance companies in the US and India. Dr. Srivastava was invited as an honorable speaker to Drug Safety & Pharmacovigilance Congress events in the UK, US and India in Jan 2012, 2013 and 2017. He has brought two cancer drugs and a vaccine in global market for approx.  $3 – 3.5 billion global sales.

Dr. Srivastava has published more than 85 papers in national and international journals, more than 120 abstracts, three book chapters and has written two patents. He is recipient of numerous national and international medical awards and recognition from the United Nations, Ministry of Health, Japan, and Department of Army, Walter Reed Army Medical Center and Walter Reed Army Institute of Research, Washington DC, USA. He served as medical advisor to Poniard Pharmaceutical for small cell lung cancer in the US, EU and India.

Dr. Srivastava is a member of numerous prestigious organizations: America’s Top Oncologist of the years 2007- 2011, Breast Cancer Foundation, Indian Society of Oncology, American Society of Clinical Oncology, American Society for Therapeutic Radiology & Oncology, American Association of Cancer Research and International Society of Lung Cancer. He is a strategic medical advisor and a board member for several U.S.-based pharma companies. For those companies, he provides clinical/regulatory support, and supervises cancer drug development.  Dr. Srivastava  serves as board of directors for oncology pharma companies in USA.

He received clinical, medical training and worked at renowned medical centers and pharmaceutical institutions worldwide, including Walter Reed Army Institute of Research and Medical Center, Daiichi, Sumitomo, Pharmacia, Pfizer, Sopherion Oncology, Eisai Oncology and Spectrum Pharmaceuticals. He received clinical, medical and business education from All India Institute of Medical Sciences, New Delhi, India; Academy of Medical Sciences, Czech Republic; School of Medicine Nagasaki University, Nagasaki, Japan; and Pharmaceutical Business at Rutgers University Business Management, New Jersey, USA.

Nithiya Ananthakrishnan, Senior Vice President of Data Sciences, OmniComm Systems, Inc.

Nithiya Ananthakrishnan founded Algorics and is now senior vice president of Data Sciences at OmniComm Systems, Inc. He is responsible for the development and delivery of the Acuity platform to meet clinical data analytics and risk-based monitoring (RBM) requirements. He joined OmniComm as part of the transaction in which OmniComm acquired certain assets of Algorics, and its flagship solution Acuity, which allows researchers to assess and capture the risk profile for a clinical trial and map risks to intelligent actions as part of RBM. As a sought-after speaker and moderator, he has delivered thought-leading presentations to prestigious industry groups around the globe.